Remestemcel-L

瑞米干赛

Report date: 2026/05/07 20:00:36

Base Information

Drug NameRemestemcel-L
Drug Alias NameHuman mesenchymal stem cells - MesoblastAllogenic mesenchymal stem cell therapy (Osiris Therapeutics)remestemcel-LRemestemcel-L (Osiris Therapeutics)Prochymal +[10] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionTissue replacementsStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseDiabetes Mellitus, Type 1Myelodysplastic Syndromes +[11] 
Global Approved IndicationsGraft vs Host Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2012/01/01
Country/TerritoryCanadaUnited StatesNew Zealand +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesOsiris Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMesoblast LtdNovartis Pharma AgMallinckrodt +[5] 
Inactive CompaniesMesoblast International SarlIcahn School Of Medicine At Mount Sinai
Active IndicationsGraft vs Host Disease
Inactive IndicationsDiabetes Mellitus, Type 1Myelodysplastic SyndromesRespiratory Distress Syndrome, Adult +[10] 

Other Information

ATC CodeB05AX
Related LinksN/A